Hjem › Spiserørkreft › Michigan
Kliniske studier for Spiserørkreft i Michigan
22 studier for Spiserørkreft søker deltakere på steder i Michigan.
Byer i Michigan
- Grand Rapids14 studier
- Detroit9 studier
- Ann Arbor4 studier
- Warren3 studier
- Farmington Hills3 studier
- Clinton Township3 studier
- Canton3 studier
- Livonia3 studier
- Lansing3 studier
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- og 13 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
- og 50 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- og 68 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Pan-tumor MRD Study
- The Cancer & Hematology Centers (CHC), Grand Rapids
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06605404A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213791Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06128551ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Grand Rapids
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07431281Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- The Cancer and Hematology Centers ( Site 8912), Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06445972Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- The Cancer and Hematology Centers ( Site 6912), Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06469944A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
RekruttererFase 4
Alder 18 og eldre · Kvinner · Oppdatert 2. jul. 2026 · NCT05183126Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05005403Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Henry Ford Cancer-Detroit, Detroit
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 19. des. 2025 · NCT06065371A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- START Midwest, Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. des. 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Ann Arbor
- Massive Bio SYNERGY-AI site, Lansing
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT0345277464Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- BAMF Health, Inc., Grand Rapids
RekruttererFase 1/2
Alder 15 og eldre · Alle kjønn · Oppdatert 12. aug. 2025 · NCT06298916A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2025 · NCT05086692Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.